SML3823
KCI807
≥98% (HPLC)
别名:
5,3’-Dihydroxyflavone, 5-Hydroxy-2-(3-hydroxyphenyl)-4H-1-benzopyran-4-one
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C15H10O4
化学文摘社编号:
分子量:
254.24
UNSPSC Code:
51111800
NACRES:
NA.77
MDL number:
SMILES string
[o]1c2c([c](cc1c3cc(ccc3)O)=O)c(ccc2)O
InChI key
SZMQXDYEGKRZDG-UHFFFAOYSA-N
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
0.2 mg/mL (DMSO:EtOH (2:1),clear, warmed, clear colorless solution)
storage temp.
room temp
Quality Level
Biochem/physiol Actions
Cell penetrant, selective and potent inhibitor of the androgen receptor (AR)-ELK1 interaction
KCI807 is a cell penetrant, selective and potent inhibitor of the androgen receptor (AR)-ELK1 interaction. KCI807 interrupts association of the androgen receptor (AR) with transcription activator ELK1 (ETS family transcription factor ELK1). It potently suppresses growth of enzalutamide-resistant prostate cancer tumor xenografts in rodents.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
The Small Molecule Antagonist KCI807 Disrupts Association of the Amino-Terminal Domain of the Androgen Receptor with ELK1 by Modulating the Adjacent DNA Binding Domain
Molecular Pharmacology, 103(4), 211-220 (2023)
Rayna Rosati et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 24(24), 6509-6522 (2018-09-07)
Testosterone suppression in prostate cancer is limited by serious side effects and resistance via restoration of androgen receptor (AR) functionality. ELK1 is required for AR-dependent growth in various hormone-dependent and castration-resistant prostate cancer models. The amino-terminal domain of AR docks
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持